Analysts Set Atossa Genetics Inc. (NASDAQ:ATOS) PT at $95.00

Atossa Genetics Inc. (NASDAQ:ATOS) has been assigned a consensus rating of “Hold” from the five brokerages that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $95.00.

A number of equities analysts have recently commented on the stock. Ascendiant Capital Markets raised their target price on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Atossa Genetics in a report on Wednesday, January 21st.

Hedge Funds Weigh In On Atossa Genetics

Institutional investors have recently made changes to their positions in the company. Ameriprise Financial Inc. bought a new stake in shares of Atossa Genetics in the second quarter valued at about $2,468,000. Renaissance Technologies LLC grew its holdings in Atossa Genetics by 33.2% during the 4th quarter. Renaissance Technologies LLC now owns 2,062,838 shares of the company’s stock worth $1,217,000 after acquiring an additional 514,175 shares in the last quarter. Jane Street Group LLC purchased a new position in Atossa Genetics during the 2nd quarter valued at about $381,000. Qube Research & Technologies Ltd increased its position in Atossa Genetics by 357.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 416,374 shares of the company’s stock valued at $346,000 after purchasing an additional 325,340 shares during the period. Finally, GSA Capital Partners LLP raised its holdings in shares of Atossa Genetics by 509.0% in the 3rd quarter. GSA Capital Partners LLP now owns 310,754 shares of the company’s stock valued at $269,000 after purchasing an additional 259,725 shares in the last quarter. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Atossa Genetics Price Performance

ATOS stock opened at $5.11 on Friday. Atossa Genetics has a 12 month low of $3.76 and a 12 month high of $19.35. The firm’s 50-day moving average is $6.29 and its 200 day moving average is $10.23. The company has a market capitalization of $44.00 million, a PE ratio of -1.42 and a beta of 1.42.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.